Welcome to our dedicated page for CODEXIS SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
CODEXIS, INC. Chief Scientific Officer Stefan Lutz reported two transactions involving company securities. On February 24, 2026, he sold 5,862 shares of common stock at $1.1329 per share to satisfy tax and other withholding obligations related to vesting Restricted Stock Units, leaving him with 130,421 common shares, which include 23,299 RSUs. On February 23, 2026, he also received a grant of 316,100 stock options with an exercise price of $0.00, vesting 25% on the first anniversary of the grant date and the remaining shares in equal monthly installments over the following three years, subject to his continued employment.
MOORE ALISON reported acquisition or exercise transactions in this Form 4 filing.
CODEXIS, INC. President and CEO Alison Moore reported receiving a stock option award covering 993,000 shares of the company’s stock. The award was granted as a derivative security with no cash purchase on the grant date.
According to the terms, the option vests over four years: 25% of the shares vest on the first anniversary of the grant date, and 1/48th of the original 993,000 shares vests on each monthly anniversary thereafter. Vesting is conditioned on Dr. Moore’s continued employment through the applicable vesting dates.
Erbez Georgia reported acquisition or exercise transactions in this Form 4 filing.
Codexis, Inc. reported that officer Georgia Erbez was granted a stock option covering 316,100 shares of common stock. The option was awarded at a reported price of $0.00 per share, consistent with an equity compensation grant rather than an open-market purchase.
According to the vesting terms, the option becomes exercisable as to 25% of the shares on the first anniversary of the grant date, then as to 1/48 of the original total on each monthly anniversary thereafter. Vesting is conditioned on Erbez’s continued employment through the applicable vesting dates.
CDXS filed a Form 144 reporting a proposed sale of 5,280 shares of Common Stock tied to an RSU vesting and settlement on 02/24/2026 through Morgan Stanley Smith Barney Executive Financial Services. The filing also lists recent insider dispositions by Stefan Lutz: 4,685 shares sold on 01/07/2026 for $7,949.51 and 2,492 shares sold on 02/06/2026 for $3,257.29.
Codexis, Inc. Chief Scientific Officer Stefan Lutz reported a small share sale tied to tax withholding. On February 6, 2026, he sold 2,492 shares of common stock at $1.3071 per share, solely to cover tax or other government withholding obligations from vesting restricted stock units.
After this transaction, Lutz beneficially owned 136,283 shares of Codexis common stock, which includes 35,799 restricted stock units. The filing shows he holds the shares directly.
Codexis, Inc. insider Georgia Erbez, the company’s Chief Financial Officer and Chief Business Officer, reported a sale of common stock tied to equity compensation. On February 6, 2026, Erbez sold 3,826 shares of Codexis common stock at $1.3071 per share, solely to cover tax or other government withholding obligations arising from the vesting of restricted stock units.
Following this transaction, Erbez beneficially owned 66,810 shares of Codexis common stock, which includes 24,374 restricted stock units. The filing indicates the holdings are owned directly rather than through an intermediary entity.
Codexis, Inc. President and CEO Alison Moore, who also serves as a director, reported selling 3,826 shares of Codexis common stock on February 6, 2026 at a price of $1.3071 per share. The filing explains that these shares were sold solely to cover tax or other government withholding obligations related to the vesting of restricted stock units.
After this transaction, Moore beneficially owned 250,506 shares of Codexis common stock, which includes 136,249 restricted stock units. The ownership is reported as held directly in her name.
An affiliate of the issuer filed a notice of proposed sale of 3,291 shares of common stock, with an aggregate market value of $4,179.57. The shares are expected to be sold on 02/06/2026 on the NASDAQ through Morgan Stanley Smith Barney Executive Financial Services.
These shares were acquired on 02/06/2026 via RSU vesting and settlement from the issuer as consideration for services rendered. In the preceding three months, Kevin Norrett sold 6,123 shares for $10,389.80 on 01/07/2026 and 1,745 shares for $2,914.32 on 01/16/2026.
Codexis associated holder filed a notice of proposed sale of 2,460 shares of Codexis common stock. The shares are expected to be sold through Morgan Stanley Smith Barney on or about February 6, 2026 on the NASDAQ.
The filing lists an aggregate market value of 3124.20 for the shares to be sold and notes that 90,324,383 shares of common stock were outstanding. The 2,460 shares were acquired on February 6, 2026 via RSU vesting and settlement as consideration for services rendered.
Opaleye Management Inc., Opaleye, L.P. and James Silverman report a significant passive stake in Codexis, Inc. common stock. They beneficially own 6,789,738 shares, representing 7.52% of Codexis’s common stock, with shared voting and shared dispositive power over these shares and no sole voting or dispositive power.
The ownership percentage is based on 90,324,383 Codexis common shares outstanding as of 11/03/2025, as reported in the company’s 10-Q. The adviser also manages separate accounts that collectively hold 120,000 Codexis shares, with each account owning less than 5% of the class. The reporting persons certify the holdings were not acquired and are not held for the purpose of changing or influencing control of Codexis.